Table 1 Demographics of patients with NMOSD and healthy controls
From: Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
single-cell RNA-sequencing | Flow cytometry analysis of BTK/pBTK expression | |||
|---|---|---|---|---|
HCs (n = 5) | NMOSD (n = 12) | HCs (n = 16) | NMOSD (n = 16) | |
Female, n (%) | 5 (100) | 11 (91.6) | 14 (87.5) | 15(93.7) |
Age, median (IQR) | 46.5 (43.5–54.0) | 51.0 (49.5–60.5) | 48.5 (31.5–52.5) | 59.5 (39.5–63.0) |
Age at onset, median (IQR) | n/a | 47.5 (40.8–54.0) | n/a | 53.7 (35.0–58.7) |
Disease duration (years), median (IQR) | n/a | 3.5 (0.3–8.5) | n/a | 3.8 (2.5–7.6) |
EDSS score, median (IQR) | n/a | 4.0 (3.5–6.5) | n/a | 3.5 (2.5–7.0) |
AQP4-ab positive, n (%) | n/a | 12 (100) | n/a | 16 (100) |
Treatment before relapses, n (%) | ||||
No treatment | n/a | 7 (58.3) | n/a | 9 (56.25) |
Oral corticosteroids | 5 (41.7) | 7 (43.75) | ||